DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this compound. Additional details are available on the belinostat profile page.
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 206256
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Approval Date:||Jul 3, 2014||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Jul 3, 2021|
|Regulatory Exclusivity Use:||TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA|
|Patent:||Get Started Free||Patent Expiration:||Sep 27, 2021||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
|Patented Use:||TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL).|
|Patent:||Get Started Free||Patent Expiration:||Oct 27, 2027||Product Flag?||Y||Substance Flag?||Delist Request?|
Complete Access Available with Subscription